The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

June is Myasthenia Gravis Awareness month. We are trying to raise awareness through various activities. One such activity is ...

Despite acknowledging that efgartigimod (Vyvgart), can 'improve symptoms and people’s ability to carry out their normal ...

Early diagnosis and treatment of generalized myasthenia gravis (MG) are important to achieve symptomatic control and limit ...

"Psychological assessments are essential in the management of myasthenia gravis, as the condition is frequently associated ...

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...

Mayor Muriel Bowser’s proposed budget for Fiscal Year 2026 would leave more than 25,000 D.C. residents without health ...

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) ...

Myasthenia gravis is a rare, chronic autoimmune disorder that causes serious muscle weakness.

Josie Hasan, 36, from Plymouth, is a doting mum to her girls, Becca, nine, and Sophie, six. Josie was diagnosed with stage 3c ...